FDA Approves OXYCODONE AND ACETAMINOPHEN — Rhodes Pharmaceuticals LLC

Rhodes Pharmaceuticals announced on August 28, 2014, that it received FDA approval for ANDA 201278, launching a generic version of the potent opioid combination formulation OxyCODONE AND ACETAMINOPHEN. This move solidifies Rhodes' footprint in the chronic pain market and creates significant pricing pressure on the original branded product by adding a lower-cost alternative for consumers and payers.